CN111467475A - Pharmaceutical composition for increasing laying rate of laying hens and preparation and application thereof - Google Patents
Pharmaceutical composition for increasing laying rate of laying hens and preparation and application thereof Download PDFInfo
- Publication number
- CN111467475A CN111467475A CN202010469175.2A CN202010469175A CN111467475A CN 111467475 A CN111467475 A CN 111467475A CN 202010469175 A CN202010469175 A CN 202010469175A CN 111467475 A CN111467475 A CN 111467475A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- powder
- semen
- laying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title description 9
- 239000000843 powder Substances 0.000 claims abstract description 58
- 210000000582 semen Anatomy 0.000 claims abstract description 57
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 20
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 20
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 20
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 20
- 229960000367 inositol Drugs 0.000 claims abstract description 20
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims abstract description 20
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 12
- 244000268590 Euryale ferox Species 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 3
- 240000008790 Musa x paradisiaca Species 0.000 claims description 3
- 235000015266 Plantago major Nutrition 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 5
- 210000000952 spleen Anatomy 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 244000144977 poultry Species 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 210000004994 reproductive system Anatomy 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 238000010792 warming Methods 0.000 abstract description 2
- 241000600871 Euryale <brittle star> Species 0.000 abstract 1
- 230000017448 oviposition Effects 0.000 description 10
- 238000009395 breeding Methods 0.000 description 8
- 230000001488 breeding effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000013601 eggs Nutrition 0.000 description 7
- 244000144972 livestock Species 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- -1 synthetic Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pregnancy & Childbirth (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a pharmaceutical composition for improving the laying rate of laying hens, which comprises the following components in parts by weight: 30-90 parts of cortex lycii radicis, 30-60 parts of cortex mori radicis, 15-30 parts of semen euryales, 9-18 parts of polygala tenuifolia, 9-18 parts of semen plantaginis salted, 3-9 parts of semen lepidii, 15-30 parts of cyclodipeptide powder, 9-18 parts of fishbone powder, 0.05-0.5 part of calcium pantothenate and 0.5-5 parts of inositol. The invention exerts the synergistic effect among the medicines, nourishes essence and blood, activates and nourishes yin blood, has the effects of activating blood, warming kidney, strengthening spleen and stomach, invigorating qi and blood and making reproductive system younger for poultry, and can effectively improve the laying rate.
Description
Technical Field
The invention relates to the technical field related to livestock breeding, in particular to a functionalized veterinary traditional Chinese medicine composition, a preparation process and an application method thereof.
Background
With the improvement of living standard, the health care consciousness of people is gradually enhanced, the people are sublimated when pursuing the living idea, return to nature and return to nature, and the requirements on food structure, nutritive value and food safety are higher and higher; people urgently need green livestock and poultry products which are free of pollution, residue, public nuisance, carcinogenesis, teratogenesis and mutation, natural and environment-friendly. How to reduce or not use chemical, synthetic, hormone and antibiotic medicines and ensure the breeding and production of pollution-free, green, environment-friendly and safe eggs becomes an important problem to be solved by urgent needs of livestock raising, veterinarians and breeding enterprises. In order to get rid of the harm of diseases and animal food residues to human beings, people use Chinese herbal medicines as additives to solve the trouble and worry of food safety.
Eggs are common food for residents in China and are important sources for protein intake of human bodies. The laying hens have the unique physiological characteristics of high body temperature, vigorous basal metabolism and rapid digestion, absorption and excretion of the feed. Laying hens are under the stress of cage culture, continuous ovulation and egg laying, so that a large amount of free radicals are generated in the bodies. Although a proper amount of free radicals have the functions of killing germs and regulating immunity, excessive free radicals can generate superoxide reaction on biological macromolecules, so that the change of cell structures and functions is caused, and the important reason for causing many diseases is that the excessive free radicals can generate superoxide reaction on the biological macromolecules. This further causes a problem of low laying rate, resulting in a vicious circle. For a long time, laying hen breeding relies on a farmer free-range mode. The free-ranging scale is small, the number is small, and the market demand cannot be met. The laying hen breeding is developed in a large-scale and intensive breeding mode. However, the traditional breeding technology cannot meet the requirement of large-scale breeding, and the disease prevention consciousness of farmers is weak, so that the types of epidemic diseases of the laying hens are increased, the disease condition is complicated, and the disease is difficult to prevent and treat. In order to reduce the occurrence of diseases and promote the growth and the laying rate, the addition of medicines such as chemistry, synthesis, hormone, antibiotics, trace elements and the like into the feed becomes an accessory means; in addition, the clinical use of drugs is inappropriate, and the large dose and the repeated use are very common, so that the drug resistance and the drug resistance of pathogenic microorganisms are continuously enhanced; the clinical manifestations of acute morbidity, quick infection, mixed infection, poor treatment effect and high mortality rate often cause serious cachexia that diagnosis is difficult to make and effective prevention and control measures are taken in time; meanwhile, the quality of eggs is difficult to guarantee.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for improving the laying rate of laying hens and preparation and application thereof.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows.
A pharmaceutical composition for improving the laying rate of laying hens comprises the following components in parts by weight: 30-90 parts of cortex lycii radicis, 30-60 parts of cortex mori radicis, 15-30 parts of semen euryales, 9-18 parts of polygala tenuifolia, 9-18 parts of semen plantaginis salted, 3-9 parts of semen lepidii, 15-30 parts of cyclodipeptide powder, 9-18 parts of fishbone powder, 0.05-0.5 part of calcium pantothenate and 0.5-5 parts of inositol.
As a preferable technical scheme of the invention, the pharmaceutical composition comprises the following components in parts by weight: 45-75 parts of cortex lycii radicis, 45-75 parts of cortex mori radicis, 18-28 parts of semen euryales, 12-16 parts of polygala tenuifolia, 12-16 parts of semen plantaginis salted, 4-8 parts of semen lepidii, 18-28 parts of cyclodipeptide powder, 12-16 parts of fishbone powder, 0.1-0.3 part of calcium pantothenate and 1-3 parts of inositol.
As a preferable technical scheme of the invention, the pharmaceutical composition comprises the following components in parts by weight: 60 parts of cortex lycii radicis, 45 parts of cortex mori radicis, 22 parts of semen euryales, 13.5 parts of polygala tenuifolia, 13.5 parts of salted plantain seed, 6 parts of semen lepidii, 22 parts of cyclodipeptide powder, 13.5 parts of fishbone powder, 0.2 part of calcium pantothenate and 2 parts of inositol.
As a preferable technical scheme of the invention, the pharmaceutical composition comprises the following components in parts by weight: 48 parts of cortex lycii radicis, 55 parts of cortex mori radicis, 25 parts of semen euryales, 12 parts of polygala tenuifolia, 14 parts of semen plantaginis preparata, 5 parts of semen lepidii, 24 parts of cyclodipeptide powder, 13 parts of fishbone powder, 0.2 part of calcium pantothenate and 1.5 parts of inositol.
As a preferable technical scheme of the invention, the pharmaceutical composition comprises the following components in parts by weight: 70 parts of cortex lycii radicis, 48 parts of cortex mori radicis, 28 parts of semen euryales, 15 parts of polygala tenuifolia, 13 parts of semen plantaginis preparata, 7 parts of semen lepidii, 20 parts of cyclic dipeptide powder, 16 parts of fishbone powder, 0.15 part of calcium pantothenate and 2 parts of inositol.
As a preferable technical scheme of the invention, the pharmaceutical composition comprises the following components in parts by weight: 45 parts of cortex lycii radicis, 45 parts of cortex mori radicis, 18 parts of semen euryales, 12 parts of polygala tenuifolia, 12 parts of semen plantaginis preparata, 4 parts of semen lepidii, 18 parts of cyclodipeptide powder, 12 parts of fishbone powder, 0.1 part of calcium pantothenate and 1 part of inositol.
As a preferable technical scheme of the invention, the pharmaceutical composition comprises the following components in parts by weight: 75 parts of cortex lycii radicis, 75 parts of cortex mori radicis, 28 parts of semen euryales, 16 parts of polygala tenuifolia, 16 parts of semen plantaginis preparata, 8 parts of semen lepidii, 28 parts of cyclodipeptide powder, 16 parts of fishbone powder, 0.3 part of calcium pantothenate and 3 parts of inositol.
A method for preparing a pharmaceutical composition for improving the laying rate of laying hens comprises the steps of weighing the components in parts by weight, directly mixing the components, crushing the mixture into fine powder, sieving the fine powder with a 200-mesh sieve, and preparing the powder.
Adopt the produced beneficial effect of above-mentioned technical scheme to lie in: the traditional Chinese veterinary medicine has the advantages of small toxic and side effects, no drug resistance, difficult residue and the like, is a pure natural medicine which is applied by human beings at first, and plays a great role in preventing and treating diseases of cultured animals, improving the immunity and the anti-stress capability of the cultured animals, promoting growth and development and the like in the veterinary medicine industry as a treasure in the world medical history of Chinese nationality. According to the dialectical view of traditional Chinese medicine, exogenous pathogenic factors are easy to attack in the egg laying process of poultry, and cold, dampness and heat pathogens (including bacteria and viruses) are mainly used, and feed malnutrition and the like can also be generalized in the exogenous range. Environmental emergency factors, which can affect the functional activities of viscera and qi and blood, thus affecting the spiritual mood of livestock and poultry, and affecting the regulation of Chong and ren functions, so called "pathogenic factors due to depression". The thoroughfare vessel and governor vessel are involved in the belt vessels due to the damage of the meridians and collaterals, and the egg laying of birds is reduced if the vessels are not functioning properly. Constitutional factors refer to the intrinsic factors of constitutional weakness, mainly the dysfunction of kidney, liver, heart and spleen, which results in deficiency of both qi and blood, insufficiency of thoroughfare and conception vessels, and insecurity of belt vessels. Imbalance of qi and blood, easy consumption of blood, often causes the body to be in the state of insufficient blood and deficient qi. The zang-fu organs are abnormal in function, mainly involving kidney, liver, heart and spleen. The invention exerts the synergistic effect among the medicines, nourishes essence and blood, activates and nourishes yin and blood, and has the effects of activating blood, warming kidney, strengthening spleen and stomach, invigorating qi and blood and making reproductive system younger for poultry; is nontoxic and harmless to the livestock; is suitable for free-range laying hens after 19 weeks old, and can effectively improve the laying rate.
Detailed Description
The following examples illustrate the invention in detail. The raw materials and various devices used in the invention are conventional commercially available products, and can be directly obtained by market purchase.
In the following description of embodiments, for purposes of explanation and not limitation, specific details are set forth, such as particular system structures, techniques, etc. in order to provide a thorough understanding of the embodiments of the present application. It will be apparent, however, to one skilled in the art that the present application may be practiced in other embodiments that depart from these specific details. In other instances, detailed descriptions of well-known systems, devices, circuits, and methods are omitted so as not to obscure the description of the present application with unnecessary detail.
It will be understood that the terms "comprises" and/or "comprising," when used in this specification and the appended claims, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
It should also be understood that the term "and/or" as used in this specification and the appended claims refers to and includes any and all possible combinations of one or more of the associated listed items.
As used in this specification and the appended claims, the term "if" may be interpreted contextually as "when", "upon" or "in response to" determining "or" in response to detecting ". Similarly, the phrase "if it is determined" or "if a [ described condition or event ] is detected" may be interpreted contextually to mean "upon determining" or "in response to determining" or "upon detecting [ described condition or event ]" or "in response to detecting [ described condition or event ]".
Furthermore, in the description of the present application and the appended claims, the terms "first," "second," "third," and the like are used for distinguishing between descriptions and not necessarily for describing or implying relative importance.
Reference throughout this specification to "one embodiment" or "some embodiments," or the like, means that a particular feature, structure, or characteristic described in connection with the embodiment is included in one or more embodiments of the present application. Thus, appearances of the phrases "in one embodiment," "in some embodiments," "in other embodiments," or the like, in various places throughout this specification are not necessarily all referring to the same embodiment, but rather "one or more but not all embodiments" unless specifically stated otherwise. The terms "comprising," "including," "having," and variations thereof mean "including, but not limited to," unless expressly specified otherwise.
Example 1
A pharmaceutical composition for improving the laying rate of laying hens comprises the following components in parts by weight: 60 parts of cortex lycii radicis, 45 parts of cortex mori radicis, 22 parts of semen euryales, 13.5 parts of polygala tenuifolia, 13.5 parts of salted plantain seed, 6 parts of semen lepidii, 22 parts of cyclodipeptide powder, 13.5 parts of fishbone powder, 0.2 part of calcium pantothenate and 2 parts of inositol.
The preparation method comprises weighing the above materials in parts by weight, directly mixing the above materials, pulverizing into fine powder, sieving with 200 mesh sieve, and making into powder.
Example 2
The present embodiment is different from embodiment 1 in that: the pharmaceutical composition comprises the following components in parts by weight: 48 parts of cortex lycii radicis, 55 parts of cortex mori radicis, 25 parts of semen euryales, 12 parts of polygala tenuifolia, 14 parts of semen plantaginis preparata, 5 parts of semen lepidii, 24 parts of cyclodipeptide powder, 13 parts of fishbone powder, 0.2 part of calcium pantothenate and 1.5 parts of inositol.
The preparation method comprises weighing the above materials in parts by weight, directly mixing the above materials, pulverizing into fine powder, sieving with 200 mesh sieve, and making into powder.
Example 3
The present embodiment is different from embodiment 1 in that: the pharmaceutical composition comprises the following components in parts by weight: 70 parts of cortex lycii radicis, 48 parts of cortex mori radicis, 28 parts of semen euryales, 15 parts of polygala tenuifolia, 13 parts of semen plantaginis preparata, 7 parts of semen lepidii, 20 parts of cyclic dipeptide powder, 16 parts of fishbone powder, 0.15 part of calcium pantothenate and 2 parts of inositol.
The preparation method comprises weighing the above materials in parts by weight, directly mixing the above materials, pulverizing into fine powder, sieving with 200 mesh sieve, and making into powder.
Example 4
The present embodiment is different from embodiment 1 in that: the pharmaceutical composition comprises the following components in parts by weight: 45 parts of cortex lycii radicis, 45 parts of cortex mori radicis, 18 parts of semen euryales, 12 parts of polygala tenuifolia, 12 parts of semen plantaginis preparata, 4 parts of semen lepidii, 18 parts of cyclodipeptide powder, 12 parts of fishbone powder, 0.1 part of calcium pantothenate and 1 part of inositol.
The preparation method comprises weighing the above materials in parts by weight, directly mixing the above materials, pulverizing into fine powder, sieving with 200 mesh sieve, and making into powder.
Example 5
The present embodiment is different from embodiment 1 in that: the pharmaceutical composition comprises the following components in parts by weight: 75 parts of cortex lycii radicis, 75 parts of cortex mori radicis, 28 parts of semen euryales, 16 parts of polygala tenuifolia, 16 parts of semen plantaginis preparata, 8 parts of semen lepidii, 28 parts of cyclodipeptide powder, 16 parts of fishbone powder, 0.3 part of calcium pantothenate and 3 parts of inositol.
The preparation method comprises weighing the above materials in parts by weight, directly mixing the above materials, pulverizing into fine powder, sieving with 200 mesh sieve, and making into powder.
Example 6 safety test
The powder of the pharmaceutical composition of examples 1-5 of the invention is mixed with the feed according to the proportion of 1:100 and evenly stirred, and then the layer chicken is fed with the evenly stirred feed and continuously fed for 14 days, and the layer chicken is normal in ingestion and growth and has no abnormal occurrence. Feeding the mice with the uniformly mixed feed, continuously feeding and observing for 14 days, wherein death and abnormal toxic reaction are not found in the test period, and after the test is finished, dissecting the test mice, and observing the liver, the kidney, the spleen, the stomach, the heart, the lung and the intestines, wherein abnormal changes are not found. According to the acute toxicity standard, the product belongs to the nontoxic grade.
Example 7 cultivation test
A control test is carried out in a Gao city culture area, the powder of the pharmaceutical composition of the embodiment 1-5 of the invention and feed are mixed and stirred uniformly according to the proportion of 1:100, 6000 laying hens at the age of 50 weeks in the same henhouse are divided into six groups of 1000 laying hens, wherein one group is fed with common feed (without the pharmaceutical composition of the invention) as a control group, and the rest five groups are respectively fed with the feed added with the pharmaceutical composition of the invention of the embodiment 1-5; the rest daily management is the same, the daily management is carried out according to the conventional operation, the egg laying of each group of laying hens is respectively recorded and divided into 5 time periods, each time period is one week, and the egg laying condition of the laying hens is recorded as follows:
table 1 egg production rate record table;
| age of egg-laying day (week) | Group 1 (example 1) | Group 2 (example 2) | Group 3 (example 3) | Group 4 (example 4) | Group 5 (example 5) | Group 6 (control group) |
| 51 | 85％ | 83％ | 81％ | 79％ | 82％ | 71％ |
| 52 | 87％ | 85％ | 84％ | 80％ | 85％ | 77％ |
| 53 | 92％ | 89％ | 85％ | 89％ | 88％ | 77.5％ |
| 54 | 94％ | 92％ | 89％ | 91％ | 90％ | 79％ |
| 55 | 94％ | 93％ | 93％ | 94％ | 93.5％ | 82.1％ |
Table 2 egg laying weight table (units: grams);
| age of egg-laying day (week) | Group 1 (example 1) | Group 2 (example 2) | Group 3 (example 3) | Group 4 (example 4) | Group 5 (example 5) | Group 6 (control group) |
| 51 | 60.1 | 60.0 | 58.7 | 55.1 | 59.2 | 52.1 |
| 52 | 62.6 | 62.2 | 59.6 | 61.5 | 60.1 | 55.3 |
| 53 | 65.3 | 65.0 | 64.2 | 62.7 | 63.0 | 58.2 |
| 54 | 67.1 | 66.5 | 66.1 | 64.3 | 65.4 | 59.7 |
| 55 | 70.4 | 68.2 | 69.9 | 68.6 | 69.0 | 62.4 |
Table 3 table of soft-preserved and preserved-sand egg laying rates;
| age of egg-laying day (week) | Group 1 (example 1) | Group 2 (example 2) | Group 3 (example 3) | Group 4 (example 4) | Group 5 (example 5) | Group 6 (control group) |
| 51 | 3.2％ | 3.1％ | 3.4％ | 3.6％ | 3.3％ | 5.1％ |
| 52 | 3.2％ | 3.0％ | 3.4％ | 3.4％ | 3.22％ | 5.0％ |
| 53 | 3.1％ | 3.0％ | 3.2％ | 3.15％ | 3.2％ | 4.5％ |
| 54 | 2.9％ | 2.95％ | 3.1％ | 3.1％ | 3.05％ | 4.0％ |
| 55 | 2.5％ | 2.8％ | 3.1％ | 2.9％ | 2.7％ | 4.0％ |
The test results show that after the laying hens are fed with the feed, the laying rate is improved by 8-15%, the egg weight is averagely increased by 3-8g, and the soft preserved eggs and the preserved sand eggs are obviously reduced.
The above-mentioned embodiments are only used for illustrating the technical solutions of the present invention, and not for limiting the same; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; such modifications and substitutions do not substantially depart from the spirit and scope of the embodiments of the present invention, and are intended to be included within the scope of the present invention.
Claims (8)
1. A pharmaceutical composition for increasing laying rate of laying hens is characterized in that: the pharmaceutical composition comprises the following components in parts by weight: 30-90 parts of cortex lycii radicis, 30-60 parts of cortex mori radicis, 15-30 parts of semen euryales, 9-18 parts of polygala tenuifolia, 9-18 parts of semen plantaginis salted, 3-9 parts of semen lepidii, 15-30 parts of cyclodipeptide powder, 9-18 parts of fishbone powder, 0.05-0.5 part of calcium pantothenate and 0.5-5 parts of inositol.
2. The pharmaceutical composition for increasing laying rate of laying hens according to claim 1, wherein: the pharmaceutical composition comprises the following components in parts by weight: 45-75 parts of cortex lycii radicis, 45-75 parts of cortex mori radicis, 18-28 parts of semen euryales, 12-16 parts of polygala tenuifolia, 12-16 parts of semen plantaginis salted, 4-8 parts of semen lepidii, 18-28 parts of cyclodipeptide powder, 12-16 parts of fishbone powder, 0.1-0.3 part of calcium pantothenate and 1-3 parts of inositol.
3. The pharmaceutical composition for increasing laying rate of laying hens according to claim 1, wherein: the pharmaceutical composition comprises the following components in parts by weight: 60 parts of cortex lycii radicis, 45 parts of cortex mori radicis, 22 parts of semen euryales, 13.5 parts of polygala tenuifolia, 13.5 parts of salted plantain seed, 6 parts of semen lepidii, 22 parts of cyclodipeptide powder, 13.5 parts of fishbone powder, 0.2 part of calcium pantothenate and 2 parts of inositol.
4. The pharmaceutical composition for increasing laying rate of laying hens according to claim 1, wherein: the pharmaceutical composition comprises the following components in parts by weight: 48 parts of cortex lycii radicis, 55 parts of cortex mori radicis, 25 parts of semen euryales, 12 parts of polygala tenuifolia, 14 parts of semen plantaginis preparata, 5 parts of semen lepidii, 24 parts of cyclodipeptide powder, 13 parts of fishbone powder, 0.2 part of calcium pantothenate and 1.5 parts of inositol.
5. The pharmaceutical composition for increasing laying rate of laying hens according to claim 1, wherein: the pharmaceutical composition comprises the following components in parts by weight: 70 parts of cortex lycii radicis, 48 parts of cortex mori radicis, 28 parts of semen euryales, 15 parts of polygala tenuifolia, 13 parts of semen plantaginis preparata, 7 parts of semen lepidii, 20 parts of cyclic dipeptide powder, 16 parts of fishbone powder, 0.15 part of calcium pantothenate and 2 parts of inositol.
6. The pharmaceutical composition for increasing laying rate of laying hens according to claim 1, wherein: the pharmaceutical composition comprises the following components in parts by weight: 45 parts of cortex lycii radicis, 45 parts of cortex mori radicis, 18 parts of semen euryales, 12 parts of polygala tenuifolia, 12 parts of semen plantaginis preparata, 4 parts of semen lepidii, 18 parts of cyclodipeptide powder, 12 parts of fishbone powder, 0.1 part of calcium pantothenate and 1 part of inositol.
7. The pharmaceutical composition for increasing laying rate of laying hens according to claim 1, wherein: the pharmaceutical composition comprises the following components in parts by weight: 75 parts of cortex lycii radicis, 75 parts of cortex mori radicis, 28 parts of semen euryales, 16 parts of polygala tenuifolia, 16 parts of semen plantaginis preparata, 8 parts of semen lepidii, 28 parts of cyclodipeptide powder, 16 parts of fishbone powder, 0.3 part of calcium pantothenate and 3 parts of inositol.
8. A method for preparing a pharmaceutical composition for improving the laying rate of laying hens is characterized by comprising the following steps: weighing the material components according to the weight part ratio, directly mixing the medicine components, crushing the medicine components into fine powder, sieving the fine powder by a 200-mesh sieve, and preparing the powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010469175.2A CN111467475A (en) | 2020-05-28 | 2020-05-28 | Pharmaceutical composition for increasing laying rate of laying hens and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010469175.2A CN111467475A (en) | 2020-05-28 | 2020-05-28 | Pharmaceutical composition for increasing laying rate of laying hens and preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111467475A true CN111467475A (en) | 2020-07-31 |
Family
ID=71763489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010469175.2A Pending CN111467475A (en) | 2020-05-28 | 2020-05-28 | Pharmaceutical composition for increasing laying rate of laying hens and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111467475A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115024431A (en) * | 2022-06-23 | 2022-09-09 | 北京都润科技有限公司 | Heat stress reducing feed additive for raising laying hens and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885215A (en) * | 2011-07-19 | 2013-01-23 | 孙登建 | Chinese herbal medicine additive for preparing laying duck feed |
| CN104738346A (en) * | 2015-03-25 | 2015-07-01 | 祥云县滴水桥种植养殖农民专业合作社 | Breeding method for laying hen |
| CN106069869A (en) * | 2016-07-01 | 2016-11-09 | 张雨 | A kind of sterilization bedding and padding for breeding layer chicken field |
| CN107373181A (en) * | 2017-09-11 | 2017-11-24 | 殷红丽 | A kind of egg feedstuff |
| CN108668997A (en) * | 2018-04-13 | 2018-10-19 | 泰安市欣悦饲料科技有限公司 | A kind of method for breeding improving performance in layers |
| CN109999100A (en) * | 2019-05-20 | 2019-07-12 | 韩向新 | A kind of pharmaceutical composition improving free-ranging laying hen egg yield |
-
2020
- 2020-05-28 CN CN202010469175.2A patent/CN111467475A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885215A (en) * | 2011-07-19 | 2013-01-23 | 孙登建 | Chinese herbal medicine additive for preparing laying duck feed |
| CN104738346A (en) * | 2015-03-25 | 2015-07-01 | 祥云县滴水桥种植养殖农民专业合作社 | Breeding method for laying hen |
| CN106069869A (en) * | 2016-07-01 | 2016-11-09 | 张雨 | A kind of sterilization bedding and padding for breeding layer chicken field |
| CN107373181A (en) * | 2017-09-11 | 2017-11-24 | 殷红丽 | A kind of egg feedstuff |
| CN108668997A (en) * | 2018-04-13 | 2018-10-19 | 泰安市欣悦饲料科技有限公司 | A kind of method for breeding improving performance in layers |
| CN109999100A (en) * | 2019-05-20 | 2019-07-12 | 韩向新 | A kind of pharmaceutical composition improving free-ranging laying hen egg yield |
Non-Patent Citations (2)
| Title |
|---|
| 李广勋: "《中药药理毒理与临床》", 31 December 1992, 天津科技翻译出版公司 * |
| 胡功政等: "《新全实用兽药手册》", 30 September 2009, 河南科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115024431A (en) * | 2022-06-23 | 2022-09-09 | 北京都润科技有限公司 | Heat stress reducing feed additive for raising laying hens and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001500364A (en) | Feed | |
| CN107912360B (en) | White feather broiler feeding mode | |
| CN113812528A (en) | Plant extract additive for improving intestinal health of livestock and poultry | |
| CN104521891A (en) | Systematic nutrition scheme for sow to increase number of market commercial pigs each year | |
| CN106107192B (en) | One hatching egg feed additive for fowls and its application | |
| CN111467475A (en) | Pharmaceutical composition for increasing laying rate of laying hens and preparation and application thereof | |
| CN109221606A (en) | A kind of nonreactive shrimp crab mulberry leaf liquid feed additive and the preparation method and application thereof | |
| CN112753869A (en) | Feed formula for increasing musk of forest musk deer and application of feed formula | |
| US20080044396A1 (en) | Method of Raising Livestock | |
| CN103404709B (en) | Feed additive produced from waste liquid and dregs in pharmaceutical factory and preparation method of feed additive | |
| CN105558435A (en) | Feed additive for preventing and treating silver carp hemorrhagic disease | |
| JP3834763B2 (en) | Mixed feed | |
| CN110786422A (en) | Daily ration preparation method for reducing ammonia gas content in chicken manure | |
| RU2725801C1 (en) | Method for increasing efficiency of young sturgeon fish growing | |
| CN104758347B (en) | Traditional Chinese medicine oral liquid for treating pullorum disease and preparation method thereof | |
| TW202133731A (en) | Use of nutritional composition being prepared by adding a yeast into a soybean protein culture medium and an antrodia camphorata extract to perform fermentation | |
| CN111418712A (en) | Feed additive for improving survival rate of weever and preparation method thereof | |
| CN111685078A (en) | High-quality beef cattle breeding method | |
| CN112136970A (en) | Piglet nursing compound feed and preparation method thereof | |
| CN109601742A (en) | A kind of pig feed additive, preparation method and its pannage | |
| CN109805204A (en) | A kind of compound bacteria fermented feed and preparation method thereof | |
| CN109430572A (en) | A kind of anti-chicken feed for pecking addiction | |
| CN114224988B (en) | Compound Chinese herbal medicine composition for promoting chicken to wake up and preparation method and application thereof | |
| KR102603876B1 (en) | Preparing method of a chicken feed composition, a chicken feed composition prepared therefrom and a method for raising chickens | |
| CN107396879A (en) | The cultural method of beef cattle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200731 |
|
| RJ01 | Rejection of invention patent application after publication |